Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VTP-200
- Development stage
- Unknown
- Lead developer
- Barinthus Biotherapeutics
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VTP-200 is a heterologous prime-boost immunotherapy candidate designed to treat persistent high-risk human papillomavirus (hrHPV) infection and associated low-grade cervical lesions. Developed by Barinthus Biotherapeutics (formerly Vaccitech), the regimen consists of a primary dose using a chimpanzee adenovirus vector (ChAdOx1-HPV) followed by a booster dose using a Modified Vaccinia Ankara vector (MVA-HPV). Both vectors are engineered to express multiple antigens from various high-risk HPV genotypes to stimulate a robust T-cell response capable of clearing infected cells. Although it reached Phase 1b/2 clinical trials, the program was deprioritized in 2024 following Barinthus's strategic pivot toward autoimmune and metabolic diseases and its subsequent merger with Clywedog Therapeutics.
- Brand names
- VTP-200VTP200VTP 200
- Other names
- ChAdOx1-HPVChAdOx-1-HPVChAdOx 1-HPVMVA-HPV
Beyond the preview
Go deeper on VTP-200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VTP-200.